A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-

Astellas Pharma Inc

Overview

To assess safety and efficacy of the patients with MR4 therapy in GVHD prophylaxis study who are eligible for the administration after 100 days post transplant (up to 1 year)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Bone Marrow Transplantation Graft Versus Host Disease Graft-Versus-Host Disease Graft-Vs-Host Disease

Interventions

TacrolimusDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 54 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient had enrolled in GVHD prophylaxis study. * Patient had been fully informed. Exclusion Criteria: * The patient had been not eligible for the administration after 100 days post transplant in the investigator's judgement.

Locations (4)

Unnamed facility

Chubu Region, Japan

Unnamed facility

Hokkaido Region, Japan

Unnamed facility

Kanto Region, Japan

Unnamed facility

Kyusyu Region, Japan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.